2019
Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation 2019, 99: 1287-1295. PMID: 31019293, DOI: 10.1038/s41374-019-0248-3.Peer-Reviewed Original ResearchConceptsMutant amino acidsAmino acidsStructural proteinsExtracellular matrix structural proteinsMatrix metalloproteinase-2Cancer progressionLate-stage cancer developmentMutant peptidesECM structural proteinsMatrix structural proteinsBioinformatics approachProtein mutantsProtease functionECM peptidesSuch proteasesMutantsPotential substratesCancer developmentProteaseMelanoma samplesProteinSpread of cancerTumor samplesMetalloproteinase-2Cancer microenvironment
2018
P081 ST14 protease resistant peptides, from glioblastoma multiforme mutant proteins, represent higher binding affinities as potential HLA class I epitopes
Zaman S, Chobrutskiy B, Patel J, Callahan B, Blanck G. P081 ST14 protease resistant peptides, from glioblastoma multiforme mutant proteins, represent higher binding affinities as potential HLA class I epitopes. Human Immunology 2018, 79: 121. DOI: 10.1016/j.humimm.2018.07.140.Peer-Reviewed Original ResearchJ recombinationT cell receptorAa substitutionsProtease sensitivityExtracellular matrix-related proteinsCancer developmentMatrix-related proteinsAmino acid substitutionsBinding affinitiesTransmembrane serine proteaseHigh binding affinityMutant proteinsBioinformatics approachAcid substitutionsProtease cleavageExtracellular matrixSerine proteasesMutant peptidesCytoskeletonProteasePeptide sequencesClass IBarcodesRecombinationProtein